-
BREAKING: Access Advance acquires Via Licensing Alliance’s HEVC, VVC patent pools
Read more: BREAKING: Access Advance acquires Via Licensing Alliance’s HEVC, VVC patent poolsThe pools will initially continue running independently, but the goal is to have one combined program – to eliminate market fragmentation – by this time next year, Access Advance’s CEO, Peter Moller, told ip fray.
-
BREAKING: Chinese FRAND determination in ZTE v. Samsung could come down any day now and set new Chinese speed record
Read more: BREAKING: Chinese FRAND determination in ZTE v. Samsung could come down any day now and set new Chinese speed recordA pretrial hearing in London revealed that a Chinese FRAND determination for a ZTE-Samsung SEP license is imminent.
-
BREAKING: Heath Hoglund steps down as Via Licensing Alliance President
Read more: BREAKING: Heath Hoglund steps down as Via Licensing Alliance PresidentVia Licensing Alliance President Heath Hoglund has announced today that he is leaving the company at the end of the year “for a new opportunity”.
-
UPC Roundup (1 week): clarification of standards for damages, claim construction, recall
Read more: UPC Roundup (1 week): clarification of standards for damages, claim construction, recallThis is a summary of developments in and around the Unified Patent Court (UPC) in the week since our December 7, 2025 UPC Roundup.
-
UPC’s Dusseldorf LD denies recall over indirect infringement; clarifies damages period, interim damages, non-inventiveness pleading standard
Read more: UPC’s Dusseldorf LD denies recall over indirect infringement; clarifies damages period, interim damages, non-inventiveness pleading standardNot only substantial non-infringing use in the territory covered by the patent-in-suit but also the possibility of exports to other countries weighs against a recall.
-
Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance
Read more: Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmanceLawyers representing generics makers welcomed the UPC’s decision to revoke the patent regardless of a prior EPO decision to the contrary.
-
Teva removes more than 200 patents from U.S. FDA’s Orange Book: win for FTC
Read more: Teva removes more than 200 patents from U.S. FDA’s Orange Book: win for FTCFollowing President Trump’s promise to lower the cost of drugs and a United States Federal Trade Commission investigation into a patent portfolio owned by Teva, the Israeli pharma company has asked the Food and Drug Administration to remove more than 200 improper patent listings related to asthma, diabetes, and COPD drugs, and epinephrine autoinjectors, from…
-
U.S. appeals court to Apple: now prove the value of your IP in district court (for the first time since the Samsung patent spat)
Read more: U.S. appeals court to Apple: now prove the value of your IP in district court (for the first time since the Samsung patent spat)An appellate ruling that largely upheld contempt sanctions imposed on Apple will now lead to further proceedings in district court.
Follow Us
Latest Articles
- Eyeing the AI data center boom, Via Licensing Alliance unveils new NAND pool, issues call for patents
- Ibex sues Disney and Snap in Brazil as streaming patent disputes escalate
- Brazilian court lifts ZTE’s 5G injunction against Samsung as expert rejects infringement and essentiality claims
- Podcast: interview with Dr. Peter Georg Picht, SEP and competition law expert
- Geely takes Avanci license: combination of three near-simultaneous events leaves no room for reasonable doubt